Sage Journals: Discover world-class research

Abstract

The Sleeping Beauty (SB) transposon system has been shown to mediate new gene sequence integration resulting in long-term expression. Here the effectiveness of hyperactive SB100X transposase was tested, and we found that hydrodynamic co-delivery of a firefly luciferase transposon (pT2/CaL) along with SB100X transposase (pCMV-SB100X) resulted in remarkably sustained, high levels of luciferase expression. However, after 4 weeks there was a rapid, animal-by-animal loss of luciferase expression that was not observed in immunodeficient mice. We hypothesized that this sustained, high-level luciferase expression achieved using the SB100X transposase elicits an immune response in pT2/CaL co-administered mice, which was supported by the rapid loss of luciferase expression upon challenge of previously treated animals and in naive animals adoptively transferred with splenocytes from previously treated animals. Specificity of the immune response to luciferase was demonstrated by increased cytokine expression in splenocytes after exposure to luciferase peptide in parallel with MHC I–luciferase peptide tetramer binding. This anti-luciferase immune response observed following continuous, high-level luciferase expression in vivo clearly impacts its use as an in vivo reporter. As both an immunogen and an extremely sensitive reporter, luciferase is also a useful model system for the study of immune responses following in vivo gene transfer and expression.

Get full access to this article

View all access options for this article.

References

Altman

J.D.

, Moss

P.A.

, Goulder

P.J.

, et al. (1996). Phenotypic analysis of antigen-specific T lymphocytes. Science, 274, 94–96.

Aronovich

E.L.

, Bell

J.B.

, Belur

L.R.

, et al. (2007). Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J. Gene Med., 9, 403–415.

Baus

, Liu

, Heggestad

A.D.

, et al. (2005). Hyperactive transposase mutants of the Sleeping Beauty transposon. Mol. Ther., 12, 1148–1156.

Bell

J.B.

, Podetz-Pedersen

K.M.

, Aronovich

E.L.

, et al. (2007). Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat. Protoc., 2, 3153–3165.

Bell

J.B.

, Aronovich

E.L.

, Schreifels

J.M.

, et al. (2010). Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery. Mol. Ther., 18, 1796–1802.

Belur

L.R.

, Frandsen

J.L.

, Dupuy

A.J.

, et al. (2003). Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol. Ther., 8, 501–507.

Belur

L.R.

, McIvor

R.S.

, and Wilber

(2008). Liver-directed gene therapy using the Sleeping Beauty transposon system. Methods Mol. Biol., 434, 267–276.

Belur

L.R.

, Podetz-Pedersen

K.M.

, Sorenson

B.S.

, et al. (2011). Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty transposon system. Mol. Cancer, 10, 14.

Crispe

I.N.

(2011). Liver antigen-presenting cells. J. Hepatol., 54, 357–365.

10.

Doherty

D.G.

, and O'Farrelly

(2001). Dendritic cells: regulators of hepatic immunity or tolerance?. J. Hepatol., 34, 156–160.

11.

Geurts

A.M.

, Yang

, Clark

K.J.

, et al. (2003). Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. Mol. Ther., 8, 108–117.

12.

Hwang

J.E.

, Shim

H.J.

, Park

Y.K.

, et al. (2011). Intravenous KITENIN shRNA injection suppresses hepatic metastasis and recurrence of colon cancer in an orthotopic mouse model. J. Korean Med. Sci., 26, 1439–1445.

13.

Ivics

, Hackett

P.B.

, Plasterk

R.H.

, and Izsvak

(1997). Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 91, 501–510.

14.

Izsvak

, Hackett

P.B.

, Cooper

L.J.

, and Ivics

(2010). Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays, 32, 756–767.

15.

Jeon

Y.H.

, Choi

, Kang

J.H.

, et al. (2007). Immune response to firefly luciferase as a naked DNA. Cancer Biol. Ther., 6, 781–786.

16.

Knolle

P.A.

, and Limmer

(2001). Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol., 22, 432–437.

17.

Limberis

M.P.

, Bell

C.L.

, and Wilson

J.M.

(2009). Identification of the murine firefly luciferase-specific CD8 T-cell epitopes. Gene Ther., 16, 441–447.

18.

Liu

, Song

, and Liu

(1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther., 6, 1258–1266.

19.

Liu

, Mah

, and Fletcher

B.S.

(2006). Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted Sleeping Beauty transposon. Mol. Ther., 13, 1006–1015.

20.

Manno

C.S.

, Pierce

G.F.

, Arruda

V.R.

, et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12, 342–347.

21.

Mates

, Chuah

M.K.

, Belay

, et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet., 41, 753–761.

22.

Matrai

, Cantore

, Bartholomae

C.C.

, et al. (2011). Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology, 53, 1696–1707.

23.

Mingozzi

, and High

K.A.

(2007). Immune responses to AAV in clinical trials. Curr. Gene Ther., 7, 316–324.

24.

Montini

, Held

P.K.

, Noll

, et al. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol. Ther., 6, 759–769.

25.

Mordant

, Loriot

, Lahon

, et al. (2011). Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One, 6, e26073.

26.

Muruve

D.A.

(2004). The innate immune response to adenovirus vectors. Hum. Gene Ther., 15, 1157–1166.

27.

, Clark

K.J.

, Fahrenkrug

S.C.

, and Ekker

S.C.

(2008). Transposon tools hopping in vertebrates. Brief Funct. Genomic Proteomic, 7, 444–453.

28.

Ohlfest

J.R.

, Frandsen

J.L.

, Fritz

, et al. (2005). Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood, 105, 2691–2698.

29.

Podetz-Pedersen

K.M.

, Bell

J.B.

, Steele

T.W.

, et al. (2010). Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. Hum. Gene Ther., 21, 210–220.

30.

Raper

S.E.

, Yudkoff

, Chirmule

, et al. (2002). A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther., 13, 163–175.

31.

Raper

S.E.

, Chirmule

, Lee

F.S.

, et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80, 148–158.

32.

Sims

, Willberg

, and Klenerman

(2010). MHC-peptide tetramers for the analysis of antigen-specific T cells. Expert Rev. Vaccines, 9, 765–774.

33.

Srinivasan

, and Frauwirth

K.A.

(2009). Peripheral tolerance in CD8+ T cells. Cytokine, 46, 147–159.

34.

, Zhou

, Zheng

, et al. (2011). Bioluminescence reporter gene imaging characterize human embryonic stem cell-derived teratoma formation. J. Cell. Biochem., 112, 840–848.

35.

Tiegs

, and Lohse

A.W.

(2010). Immune tolerance: what is unique about the liver. J. Autoimmun., 34, 1–6.

36.

Wilber

, Frandsen

J.L.

, Wangensteen

K.J.

, et al. (2005). Dynamic gene expression after systemic delivery of plasmid DNA as determined by in vivo bioluminescence imaging. Hum. Gene Ther., 16, 1325–1332.

37.

Wilber

, Wangensteen

K.J.

, Chen

, et al. (2007). Messenger RNA as a source of transposase for Sleeping Beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol. Ther., 15, 1280–1287.

38.

Xue

, Huang

, Nodland

S.E.

, et al. (2009). Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood, 114, 1319–1330.

39.

Yant

S.R.

, Meuse

, Chiu

, et al. (2000). Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. Genet., 25, 35–41.

40.

Yant

S.R.

, Park

, Huang

, et al. (2004). Mutational analysis of the N-terminal DNA-binding domain of Sleeping Beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol. Cell Biol., 24, 9239–9247.

41.

Zayed

, Izsvak

, Walisko

, and Ivics

(2004). Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis. Mol. Ther., 9, 292–304.

42.

Zhang

, Budker

, and Wolff

J.A.

(1999). High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther., 10, 1735–1737.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB

Cellular Immune Response Against Firefly Luciferase After Sleeping Beauty –Mediated Gene Transfer In Vivo

Abstract

Get full access to this article

References

Supplementary Material